China’s state-backed coronavirus vaccine protected 86% of people from getting COVID-19 in trials conducted in the United Arab Emirates, reported media outlets including Reuters, citing the UAE’s health ministry.
The vaccine, developed by Sinopharm unit China National Biotec Group Co., has been granted emergency use authorization in the UAE and administered to front-line medical workers, government health officials and a number of senior ministers, the reports said. The shot already has emergency authorization in China and has been administered to hundreds of thousands of people there in recent months.
The 86% efficacy rate for one of China’s leading vaccine efforts ranks among the most effective the world has seen, making it a potentially more favorable option to vaccinate large swathes of population in the developing world than front-runner Western efforts.
The Chinese shot can be transported and stored at normal refrigerated temperatures, easing distribution challenges in nations lacking deep freeze facilities and trucks required for mRNA vaccines from Pfizer Inc. and Moderna Inc., which showed higher efficacy of over 90%.
The vaccine, developed by Sinopharm unit China National Biotec Group Co., has been granted emergency use authorization in the UAE and administered to front-line medical workers, government health officials and a number of senior ministers, the reports said. The shot already has emergency authorization in China and has been administered to hundreds of thousands of people there in recent months.
The 86% efficacy rate for one of China’s leading vaccine efforts ranks among the most effective the world has seen, making it a potentially more favorable option to vaccinate large swathes of population in the developing world than front-runner Western efforts.
The Chinese shot can be transported and stored at normal refrigerated temperatures, easing distribution challenges in nations lacking deep freeze facilities and trucks required for mRNA vaccines from Pfizer Inc. and Moderna Inc., which showed higher efficacy of over 90%.
